The Danish pharmaceutical giant Novo Nordisk is expanding its factory outside Copenhagen.
Novo Nordisk is to invest 7.5 billion kroner (5.4 billion Danish kroner) to expand its factory in Bagsværd outside Copenhagen. The plans also include the construction of a new facility, which is an extension of the existing facility.
The investment will strengthen Novo Nordisk’s capacity in research and clinical studies. Specifically, additional capacity must be established within research and development work (R&D) for the production of active pharmaceutical ingredients (API) for the company’s global clinical studies, the company writes in a statement.
Read also: Record growth for Danish slimming medicine
The expansion will provide opportunities to develop Novo Nordisk’s future oral and injectable product portfolio, says Jesper Bøving as senior vice president, CMC Development at Novo Nordisk.
– Investments that will expand our clinical API capacity in Bagsværd are an important step to ensure ongoing development of our innovative product portfolio. Increasing our API capacity within R&D will be a key factor in bringing new innovations to market and meeting future patient demand, says Bøving.